Insomnia
RonJGlas Insomnia Formulation
Sleeping disorders occur for a variety of reasons but manifest themselves as hard to fall and/or stay asleep. The Ron J. Glas patent pending recipe is a pharmaceutical composition with specific finetuned concentrations and ratio’s between a number of cannabinoids including cannabigerol (CBG) as a leading molecule for the use in this new composition for successful alleviation of sleeping disorders.
Good sleep is vital for overall well-being as it provides the necessary energy for optimal functioning.
Insomnia pre-clinical study 1
In the experimental study we exposed Rats to our insomnia formula. We also exposed a control group to olive oil. After the exposure we followed the rats during both light and dark moments with both Analogic passive infrared decector (PIR) and implanted EEG electrodes. The research showed significantly that rats using our formula have less power of active and passive behaviour compared with rats that used only olive oil and baseline conditions.
Radboud University Nijmegen
Dept. Biological Psychology, Donders
Institute for Brain, Cognition and Behaviour
Male Wistar rats were used in this study as the objects. Rats that used our formula have, in both dark and light periods significantly longer sleep segments ( p=0.0016 and 0.0089) compared with rats that used regular olive oil and baseline conditions. EEG recording show that rats using our formula have significantly less power in EEG of active and passive behaviour compared to rats that used only olive oil and baseline conditions.
The experimental model used in this study allows to unravel molecules able to alter sleep architecture in normal condition (Le. increased sleeping time or retarded waking up). We also extended the study simulating a condition in which sleep is interrupted by an external stimulus (dark) forcing the subject to wake up and then retum to the sleeping phase (light).
Insomnia pre-clinical study 2
In the experimental study, we exposed Zebrafish to our specific formula. After that, we followed their movement between multiple periods of light & dark. We measured the fish movement during both periods with the interpretation that movement is inversely proportional to sleep. We found that Zebrafish treatment with our cannabinoid insomnia formulation increases the sleeping time and faster transition to sleep.
Prof. M. Memo
Dept. of Molecular and Translational Medicine
University of Brescia, Italy
The experimental model used in this study allows to unravel molecules able to alter sleep architecture in normal condition (Le. increased sleeping time or retarded waking up). We also extended the study simulating a condition in which sleep is interrupted by an external stimulus (dark) forcing the subject to wake up and then retum to the sleeping phase (light).
We found that Zebrafish treated with a specific combination of CBs (0.3 mM CBx + 0.3 mM THC + 0.26 mM CBx) showed increased sleeping time and faster transition to sleep after an external stimulus. CBx alone was unable to modify the behavioral response of Zebrafish to dark/light stimuli suggesting that it does not alter sleep pattern. Adding THC to the CB formula did not alter the behavioral profile during light periods. However, the dark-induced movement response showed a time-dependent decrease suggesting a faster transition to sleep. The full response was found only when Zebrafish were exposed to our final formula of CBx + THC + CBx.
Effects and side effects
This formula can induce restful sleep for up to 12 hours, depending on the dosage, leaving you feeling refreshed and with a healthy appetite upon waking. Its key advantage over synthetic sleeping pills lies in the presence of a basic nitrogen in its molecules and lower ki-values. These allow for lower dosages and reduced dissociation from target receptors, minimizing adverse effects while optimizing its sleep-inducing properties.
Publications
- Vaillancourt R, Gallagher S, Cameron JD, Dhalla R. Cannabis use in patients with insomnia and sleep disorders: Retrospective chart review. Can Pharm J (Ott). 2022 Apr 15;155(3):175-180. doi: 10.1177/17151635221089617. PMID: 35519083; PMCID: PMC9067069.
- Kesner AJ, Lovinger DM. Cannabinoids, Endocannabinoids and Sleep. Front Mol Neurosci. 2020 Jul 22;13:125. doi: 10.3389/fnmol.2020.00125. PMID: 32774241; PMCID: PMC7388834.